Discovering and developing transformative therapies for people with advanced liver disease

Ambys Medicines is a biotechnology company dedicated to capitalizing on advances in liver biology and regenerative medicines to develop therapies for serious liver diseases. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and targeted drug therapy, to meet the urgent need for treatments that have potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock and Takeda Pharmaceuticals.

Year Invested: 2018
Location: Redwood City, CA

Recent News

December 13, 2018
Jeff Jonker Joins Ambys Medicines as President and CEO

August 8, 2018
Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class Therapies for the Treatment of Serious Liver Diseases

August 8, 2018
Ambys Medicines Launches with $140 Million to Pioneer Regenerative Medicine Therapies for Serious Liver Diseases

Read More News

Associated Team Members

Jeffrey Finer, M.D., Ph.D.
Venture Partner

Jeffrey Tong, Ph.D.

Charles Homcy, M.D.

Neil Exter